Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

HIV and cardiovascular disease: the role of inflammation

HIV and cardiovascular disease: the role of inflammation Purpose of reviewHIV and antiretroviral therapy (ART) use are linked to an increased incidence of atherosclerotic cardiovascular disease (ASCVD). Immune activation persists in ART-treated people with HIV (PWH), and markers of inflammation (i.e. IL-6, C-reactive protein) predict mortality in this population. This review discusses underlying mechanisms that likely contribute to inflammation and the development of ASCVD in PWH.Recent findingsPersistent inflammation contributes to accelerated ASCVD in HIV and several new insights into the underlying immunologic mechanisms of chronic inflammation in PWH have been made (e.g. clonal haematopoiesis, trained immunity, lipidomics). We will also highlight potential pro-inflammatory mechanisms that may differ in vulnerable populations, including women, minorities and children.SummaryMechanistic studies into the drivers of chronic inflammation in PWH are ongoing and may aid in tailoring effective therapeutic strategies that can reduce ASCVD risk in this population. Focus should also include factors that lead to persistent disparities in HIV care and comorbidities, including sex as a biological factor and social determinants of health. It remains unclear whether ASCVD progression in HIV is driven by unique mediators (HIV itself, ART, immunodeficiency), or if it is an accelerated version of disease progression seen in the general population. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV and AIDS Wolters Kluwer Health

HIV and cardiovascular disease: the role of inflammation

Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/hiv-and-cardiovascular-disease-the-role-of-inflammation-0Q7Ak0l6gO

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/coh.0000000000000755
Publisher site
See Article on Publisher Site

Abstract

Purpose of reviewHIV and antiretroviral therapy (ART) use are linked to an increased incidence of atherosclerotic cardiovascular disease (ASCVD). Immune activation persists in ART-treated people with HIV (PWH), and markers of inflammation (i.e. IL-6, C-reactive protein) predict mortality in this population. This review discusses underlying mechanisms that likely contribute to inflammation and the development of ASCVD in PWH.Recent findingsPersistent inflammation contributes to accelerated ASCVD in HIV and several new insights into the underlying immunologic mechanisms of chronic inflammation in PWH have been made (e.g. clonal haematopoiesis, trained immunity, lipidomics). We will also highlight potential pro-inflammatory mechanisms that may differ in vulnerable populations, including women, minorities and children.SummaryMechanistic studies into the drivers of chronic inflammation in PWH are ongoing and may aid in tailoring effective therapeutic strategies that can reduce ASCVD risk in this population. Focus should also include factors that lead to persistent disparities in HIV care and comorbidities, including sex as a biological factor and social determinants of health. It remains unclear whether ASCVD progression in HIV is driven by unique mediators (HIV itself, ART, immunodeficiency), or if it is an accelerated version of disease progression seen in the general population.

Journal

Current Opinion in HIV and AIDS – Wolters Kluwer Health

Published: Sep 5, 2022

References

  • Global burden of atherosclerotic cardiovascular disease in people living with HIV
  • Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease
  • Pathogenesis of aging and age-related comorbidities in people with HIV: highlights from the HIV ACTION Workshop
  • Single-cell immune landscape of human atherosclerotic plaques
  • Limited proliferation capacity of aortic intima resident macrophages requires monocyte recruitment for atherosclerotic plaque progression
  • The macrophage in cardiac homeostasis and disease: JACC Macrophage in CVD Series (Part 4)
  • Disordered haematopoiesis and cardiovascular disease: a focus on myelopoiesis
  • HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults
  • Clonal hematopoiesis is associated with low CD4 nadir and increased residual HIV transcriptional activity in virally suppressed individuals with HIV
  • Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV
  • Microbial translocation is a cause of systemic immune activation in chronic HIV infection
  • Microbial translocation in the pathogenesis of HIV infection and AIDS
  • Gut epithelial barrier and systemic inflammation during chronic HIV infection
  • Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndromes
  • Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection
  • Plasma levels of soluble CD14 independently predict mortality in HIV infection
  • Sevelamer does not decrease lipopolysaccharide or soluble CD14 levels but decreases soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol levels in individuals with untreated HIV infection
  • Weighing in on the risks and benefits of probiotic use in HIV-infected and immunocompromised populations
  • Probiotics reduce inflammation in antiretroviral treated, HIV-infected individuals: results of the “Probio-HIV” clinical trial
  • The effects of prebiotics on microbial dysbiosis, butyrate production and immunity in HIV-infected subjects
  • Reduced levels of D-dimer and changes in gut microbiota composition after probiotic intervention in HIV-infected individuals on stable ART
  • Immunomodulation of antiretroviral drug-suppressed chronic HIV-1 infection in an oral probiotic double-blind placebo-controlled trial
  • Effects of immunonutrition in advanced human immunodeficiency virus disease: a randomized placebo-controlled clinical trial (Promaltia Study)
  • Effectiveness of nutritional treatment and synbiotic use on gastrointestinal symptoms reduction in HIV-infected patients: randomized clinical trial
  • A randomized, placebo-controlled trial assessing the effect of VISBIOME ES probiotic in people with HIV on antiretroviral therapy
  • Improving intestinal barrier using GLP-2 agonist reduces arterial inflammation in PWH
  • Elevated plasma ceramides are associated with antiretroviral therapy use and progression of carotid artery atherosclerosis in HIV infection
  • Association of lipidomic profiles with progression of carotid artery atherosclerosis in HIV infection
  • Plasma lipidomic profiles and cardiovascular events in a randomized intervention trial with the Mediterranean diet
  • Changes in lipidomic profile by antiretroviral treatment regimen: an ACTG 5257 ancillary study
  • Plasma lipidome abnormalities in people with HIV initiating antiretroviral therapy
  • Prospective analysis of lipid composition changes with antiretroviral therapy and immune activation in persons living with HIV
  • Fatty acyl composition of lysophosphatidylcholine is important in atherosclerosis
  • Saturated fatty acids engage an IRE1alpha-dependent pathway to activate the NLRP3 inflammasome in myeloid cells
  • FADS genotypes and desaturase activity estimated by the ratio of arachidonic acid to linoleic acid are associated with inflammation and coronary artery disease
  • Plasma lipid composition and risk of developing cardiovascular disease
  • Serum N-3 polyunsaturated fatty acid levels correlate with the extent of coronary plaques and calcifications in patients with acute myocardial infarction
  • Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages
  • Altered lipidome composition is related to markers of monocyte and immune activation in antiretroviral therapy treated human immunodeficiency virus (HIV) infection and in uninfected persons
  • Monocytes from HIV-infected individuals show impaired cholesterol efflux and increased foam cell formation after transendothelial migration
  • Macrophage maturation from blood monocytes is altered in people with HIV, and is linked to serum lipid profiles and activation indices: a model for studying atherogenic mechanisms
  • Adipocyte ceramides: the nexus of inflammation and metabolic disease
  • Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy
  • Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy
  • Changes in oxidized lipids drive the improvement in monocyte activation and vascular disease after statin therapy in HIV
  • Statin use in ART-treated HIV reveals an altered macrophage transcriptomic profile
  • Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)
  • Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity
  • Defining trained immunity and its role in health and disease
  • Trained immunity: an underlying driver of inflammatory atherosclerosis
  • Microbial stimulation of different Toll-like receptor signalling pathways induces diverse metabolic programmes in human monocytes
  • TLR agonists as mediators of trained immunity: mechanistic insight and immunotherapeutic potential to combat infection
  • Stimulation of PBMC and monocyte-derived macrophages via Toll-like receptor activates innate immune pathways in HIV-infected patients on virally suppressive combination antiretroviral therapy
  • IL-1Beta enriched monocytes mount massive IL-6 responses to common inflammatory triggers among chronically HIV-1 infected adults on stable antiretroviral therapy at risk for cardiovascular disease
  • Chronic HIV infection induces transcriptional and functional reprogramming of innate immune cells
  • Involvement of reactive oxygen species in cyclic stretch-induced NF-kappaB activation in human fibroblast cells
  • Molecular inflammation: underpinnings of aging and age-related diseases
  • Mitochondrial dysfunction activates cyclooxygenase 2 expression in cultured normal human chondrocytes
  • Inflammaging: disturbed interplay between autophagy and inflammasomes
  • Antiinflammatory therapy with canakinumab for atherosclerotic disease
  • Senescent phenotype induced by p90RSK-NRF2 signaling sensitizes monocytes and macrophages to oxidative stress in HIV-positive individuals
  • Effect of HIV infection and antiretroviral therapy on immune cellular functions
  • In vitro exposure of leukocytes to HIV preexposure prophylaxis decreases mitochondrial function and alters gene expression profiles
  • Anti-HIV drugs cause mitochondrial dysfunction in monocyte-derived macrophages
  • Addressing health disparities in HIV: introduction to the special issue
  • HIV infection and the risk of acute myocardial infarction
  • HIV infection and cardiovascular disease in women
  • Comparison of ischemic stroke incidence in HIV-infected and non-HIV-infected patients in a US healthcare system
  • Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women
  • Biomarkers of inflammation in HIV-infected Peruvian men and women before and during suppressive antiretroviral therapy
  • Sex-related differences in inflammatory and immune activation markers before and after combined antiretroviral therapy initiation
  • Sex and gender differences in HIV-1 infection
  • HIV-exposed uninfected infants have increased inflammation and monocyte activation
  • Increased systemic inflammation and gut permeability among women with treated HIV infection in rural Uganda
  • Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article
  • Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1
  • Connecting the immune system, systemic chronic inflammation and the gut microbiome: the role of sex
  • Altered intestinal permeability and fungal translocation in Ugandan children with human immunodeficiency virus
  • Cardiovascular disease risk among transgender women living with HIV in the United States
  • Cardiovascular disease risk factors and myocardial infarction in the transgender population
  • Assessing and addressing cardiovascular health in people who are transgender and gender diverse: a scientific statement from the American Heart Association
  • Systemic inflammation as a driver of health disparities among sexually-diverse and gender-diverse individuals
  • Relationship between economic insecurity, inflammation, monocyte activation and intestinal integrity in children living with HIV in Uganda
  • Increased carotid intima media thickness and cardiac biomarkers in HIV infected children
  • Heightened inflammation is linked to carotid intima-media thickness and endothelial activation in HIV-infected children
  • Subclinical atherosclerosis and markers of immune activation in HIV-infected children and adolescents: the CaroVIH Study
  • Subclinical vascular disease in children with human immunodeficiency virus in Uganda is associated with intestinal barrier dysfunction
  • Increased monocyte and T-cell activation in treated HIV+ Ugandan children: associations with gut alteration and HIV factors
  • Innate and adaptive abnormalities in youth with vertically acquired HIV through a multicentre cohort in Spain
  • Increased immune activation and exhaustion in HIV-infected youth
  • Composition of gut microbiota of children and adolescents with perinatal human immunodeficiency virus infection taking antiretroviral therapy in Zimbabwe
  • High abundance of genus Prevotella in the gut of perinatally HIV-infected children is associated with IP-10 levels despite therapy
  • Distinct gut microbiota profile in antiretroviral therapy-treated perinatally HIV-infected patients associated with cardiac and inflammatory biomarkers
  • Perinatally acquired HIV infection is associated with abnormal blood mitochondrial function during childhood/adolescence
  • Mitochondrial impairment in well suppressed children with perinatal HIV-infection on antiretroviral therapy
  • Persistent, albeit reduced, chronic inflammation in persons starting antiretroviral therapy in acute HIV infection
  • Abnormal levels of some biomarkers of immune activation despite very early treatment of human immunodeficiency virus
  • Residual viremia is linked to a specific immune activation profile in HIV-1-infected adults under efficient antiretroviral therapy
  • Microbial translocation is linked to a specific immune activation profile in HIV-1-infected adults with suppressed viremia
  • One of the immune activation profiles observed in HIV-1-infected adults with suppressed viremia is linked to metabolic syndrome: the ACTIVIH study